FranceCoag: a 22-year prospective follow-up of the national French cohort of patients with inherited bleeding disorders.


Journal

European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062

Informations de publication

Date de publication:
May 2019
Historique:
received: 29 06 2018
accepted: 20 11 2018
pubmed: 6 12 2018
medline: 21 9 2019
entrez: 6 12 2018
Statut: ppublish

Résumé

FranceCoag is an ongoing open prospective multicentre cohort project aimed at improving epidemiological knowledge about inherited bleeding disorders in France. The main objective of this article was to evaluate the project's progress as of the 30th December 2016. Between 1994 and this date, of the 10,047 patients included in the study, 384 (3.8%) were reported by clinicians to have died and 159 (1.6%) to be lost to follow-up. Among the remaining 9504 patients still being followed up, 5748 (60.5%) had haemophilia A, 1300 (13.7%) haemophilia B, 1980 (20.8%) von Willebrand Disease while 476 (5.0%) had another clotting factor deficiency (Factor I, II, V, combined V and VIII, VII, X, XI and XIII). The median age of the population was 32 years (Inter-quartile range (IQR) 18-50 years) at data extraction on December 30th, 2016. The subgroup of children (i.e., < 18 years old) with severe haemophilia and comprehensive information available since the first exposure to treatment was identified as the PUPs (Previously Untreated Patients) cohort. Data for the 643 children included in the PUPs' cohort had been collected since their birth. Follow-up data were collected by the clinicians in haemophilia treatment centres (HTC) every 12.9 months on median (IQR 11.4-21.3). In the PUPS cohort, data were updated every 6.2 months on median (IQR 3.7-11.7). A unique patient number assigned at study inclusion was kept at individual HTC by participating clinicians. The data collected included demographic, clinical, therapeutic and biological items on standard electronic forms. As of December 30th 2016, a plasma and serum samples was available for 2581 patients (27.1%).

Identifiants

pubmed: 30515664
doi: 10.1007/s10654-018-0468-7
pii: 10.1007/s10654-018-0468-7
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

521-532

Investigateurs

J F Abgraal (JF)
D Adjaoud (D)
S Albinni (S)
D Ancelet (D)
A Aouba (A)
B Arab (B)
L Ardillon (L)
V Barbay (V)
E Bariller (E)
C Barro (C)
B Bastenaire (B)
S Bayart (S)
S Beaussant-Cohen (S)
C Behar (C)
I Belkaïd (I)
E Benz-Lemoine (E)
C Berger (C)
K Berny (K)
M A Bertrand (MA)
P Beurrier (P)
M Bianchin (M)
J Biernat (J)
C Biron-Andreani (C)
M Blanc (M)
L Bodet (L)
J Y Borg (JY)
E Boulfroy (E)
J Bovet (J)
M E Briquel (ME)
Z Brouk (Z)
A Brunot (A)
S Castet (S)
H Chambost (H)
A Chaminade (A)
P Chamouni (P)
S Charbonneau (S)
C Chenuel (C)
B Coatmelec (B)
P Codine (P)
B Collet (B)
S Combe (S)
V Dalibard (V)
L De Lumley (L)
E De Raucourt (E)
Y Demay (Y)
A Derlon (A)
D Desprez (D)
A Deville (A)
J Dieval (J)
R d'Oiron (R)
S Donadel Claeyssens (S)
D Donadio (D)
J Douay (J)
G Drugmanne (G)
C Dumesnil (C)
C Dupont de Romemont (C)
A Durin-Assollant (A)
F Dutrillaux (F)
C Falaise (C)
A Faradji (A)
E Ferré (E)
A M Ferrer (AM)
O Feugeas (O)
M Fiks Sigaud (M)
B Fimbel (B)
J Fonlupt (J)
M Fouassier (M)
L Frenzel (L)
E Fressinaud (E)
B Frotscher (B)
V Gaboulaud (V)
S Gaillard (S)
P Gautier (P)
V Gay (V)
P Gembara (P)
S Girault (S)
E Gleizes (E)
I Goesin (I)
S Gorde (S)
J Goudemand (J)
K Gourou (K)
S Grenetier (S)
Y Gruel (Y)
V Guérin (V)
C Guérois (C)
M Guezet-Souibri (M)
B Guillet (B)
A Harroche (A)
J Hassenboehler (J)
A Hassoun (A)
G Haya-Baviera (G)
T Henni (T)
C Henrio (C)
N Hézard (N)
Y Huguenin (Y)
E Lambert (E)
T Lambert (T)
B Lartigue (B)
Y Laurian (Y)
P Lauroua (P)
V Le Cam Duchez (V)
A Leclere (A)
M Le Guyader (M)
C Le Niger (C)
A Le François (A)
F Legrand (F)
A Lienhart (A)
V Li-Thiao-Te (V)
P Lutz (P)
L Macchi (L)
C Maire (C)
C Marichez (C)
A Marie-Cardine (A)
R Marlu (R)
A Marquès-Verdier (A)
M Martin (M)
M Matingou (M)
Y Mahi (Y)
J Mercy (J)
S Meunier (S)
M Micheau (M)
V Milien (V)
P Molho (P)
B Monlibert (B)
F Monpoux (F)
A Monmartin (A)
P Moreau (P)
M Munzer (M)
R Navarro (R)
C Négrier (C)
N Nemausat (N)
P Nguyen (P)
C Normand (C)
P Nyombe (P)
C Oudot (C)
N Ounnoughene (N)
P Palamaringue (P)
B Pan Petesch (B)
C Paris (C)
A Parquet (A)
P Paugy (P)
B Pautard (B)
G Pernod (G)
N Pertuiset (N)
O Peter (O)
J Peynet (J)
S Pierre-Louis (S)
B Pignon (B)
O Pincemaille (O)
F Pineau-Vincent (F)
B Play (B)
B Polack (B)
O Pouille Lievin (O)
K Pouymayou (K)
P Pouzol (P)
A Rafowicz (A)
A Ramassamy (A)
A Rauch (A)
S Regina (S)
P Renom (P)
J Reynaud (J)
C Ricard (C)
J Risch (J)
V Robert (V)
M Roche (M)
A Rosay (A)
P Rospide (P)
C Rothschild (C)
F Rousseau (F)
L Rugeri (L)
F Sanderson (F)
I Savary (I)
P Schneider (P)
J F Schved (JF)
J Selva (J)
P Sénéchal (P)
F Sicardi (F)
P Sie (P)
C Soler (C)
N Stieltjes (N)
C Stoven (C)
Y Sultan (Y)
S Susen (S)
C Tahiri (C)
M Tamburro (M)
B Tardy (B)
E Tarral (E)
C Ternisien (C)
M F Thiercelin Legrand (MF)
S Thouvenin-Doulet (S)
V Tintillier (V)
M F Torchet (MF)
N Trillot (N)
P Tron (P)
M Trossaërt (M)
F Uettwiller (F)
J B Valentin (JB)
S Vanderbecken (S)
J P Vannier (JP)
D Vassilieff (D)
M Vicariot (M)
S Voisin (S)
F Volot (F)
A Voyer (A)
B Wibaut (B)

Références

Haemophilia. 2001 Jan;7(1):82-8
pubmed: 11136385
Br J Haematol. 2002 Feb;116(2):383-9
pubmed: 11841442
J Pediatr. 2002 Oct;141(4):548-52
pubmed: 12378196
Stud Health Technol Inform. 2008;136:51-6
pubmed: 18487707
Haemophilia. 2010 Jan;16(1):20-32
pubmed: 19845775
Arch Pediatr. 2010 Jun;17(6):618-9
pubmed: 20654808
N Engl J Med. 2013 Jan 17;368(3):231-9
pubmed: 23323899
J Pediatr. 2013 Jun;162(6):1241-4, 1244.e1
pubmed: 23333129
Blood. 2014 Nov 27;124(23):3398-408
pubmed: 25253771
Blood. 2014 Nov 27;124(23):3389-97
pubmed: 25339360
Haematologica. 2018 Jan;103(1):179-189
pubmed: 29025913

Auteurs

Alexandra Doncarli (A)

Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, France. alexandra.doncarli@santepubliquefrance.fr.

Virginie Demiguel (V)

Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, France.

Irina Guseva Canu (I)

Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, France.
Institute for Work and Health, University of Lausanne, University of Geneva, Epalinges-Lausanne, Switzerland.

Véronique Goulet (V)

Santé publique France, French national public health agency, 12 rue du Val d'Osne, 94415, Saint-Maurice, France.

Sophie Bayart (S)

Haemophilia Treatment Centre, University Hospital of Rennes, Rennes, France.

Thierry Calvez (T)

Inserm, Sorbonne University, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.

Sabine Castet (S)

Haemophilia Treatment Centre, Pellegrin Hospital, Bordeaux, France.

Vincent Dalibard (V)

Haematology and Transfusion, School of Medecine, Lille University Hospital, Lille, France.

Yohan Demay (Y)

Haemophilia Treatment Centre, APHP, Necker Hospital, Paris, France.

Birgit Frotscher (B)

Haemophilia Treatment Centre, Brabois Hospital, Nancy, France.

Jenny Goudemand (J)

Haematology and Transfusion, School of Medicine, Lille University Hospital, Institut Pasteur de Lille, EGID, Inserm, UMR 1011, Lille 2 University, Lille, France.

Thierry Lambert (T)

Haemophilia Treatment Centre, APHP, Bicêtre Hospital, Le Kremlin Bicêtre, France.

Vanessa Milien (V)

Haemophilia Treatment Centre, APHM, Children Hospital La Timone, Marseille, France.

Caroline Oudot (C)

Haemophilia Treatment Centre, Dupuytren Hospital, Limoges, France.

Thomas Sannié (T)

French Haemophilia Association (AFH), Paris, France.

Hervé Chambost (H)

Haemophilia Treatment Centre, APHM, Children Hospital La Timone, Aix Marseille University, INSERM, INRA, C2VN, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH